⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNPR News
Monopar Therapeutics Inc. Common Stock
Form 8-K
sec.gov
MNPR
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
globenewswire.com
MNPR
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR